NAV

呃ythromycin

Identification

Summary

呃ythromycinis a macrolide antibiotic used to treat and prevent a variety of bacterial infections.

Brand Names
Aktipak、Apo-Erythro-S Benzamycin,一些非常,Ery-tab, Eryc, Erygel, Eryped, Erythro, Erythrocin, Erythrocin Stearate
Generic Name
呃ythromycin
DrugBank Accession Number
DB00199
Background

呃ythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists ofAzithromycin,Clarithromycin,Spiramycinand others. It was originally discovered in 1952.20呃ythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.20,21It is available for administration in various forms, including intravenous, topical, and eye drop preparations.20

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
MOL SDF PDB SMILES InChI
Similar Structures
Weight
Average: 733.9268
Monoisotopic: 733.461241235
Chemical Formula
C37H67NO13
Synonyms
  • 3''-O-demethylerythromycin
  • Abomacetin
  • 呃itromicina
  • 呃ythromycin
  • 呃ythromycin A
  • 呃ythromycin C
  • érythromycine
  • 呃ythromycinum
External IDs
  • NSC-55929

Pharmacology

Indication

呃ythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria.21The indications for erythromycin have been summarized by body system below:

Respiratory infections

Mild to moderate upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with erythromycin.21Mild to moderate lower-respiratory tract infections due to susceptible strains of Streptococcus pneumoniae or Streptococcus pyogenes may also be treated. Erythromycin treats listeriosis caused by Listeria monocytogenes may also be treated with erythromycin.21呃ythromycin is indicated to treat pertussis (whooping cough) caused by Bordetella pertussis. It is effective in eliminating the causative organism from the nasopharynx of infected individuals, rendering them noninfectious. Clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacteria.21Respiratory tract infections due to Mycoplasma pneumoniae may also be treated with erythromycin.21Despite the fact that no controlled clinical efficacy studies have been conducted to this date, in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in Legionnaires’ Disease.21Finally, erythromycin is indicated to treat diphtheria and other infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers.21In addition to the prevention of diphtheria, erythromycin can be used to prevent rheumatic fever in penicillin intolerant patients.21

Skin infections

Mild to moderate skin or skin structure infections caused by Streptococcus pyogenes or Staphylococcus aureus may be treated with erythromycin, however, resistant staphylococcal organisms may emerge.21呃ythromycin can also be used to treat erythrasma, an infectious condition caused by Corynebacterium minutissimum.21

Gastrointestinal infections

Intestinal amebiasis caused by Entamoeba histolytica can be treated with oral erythromycin. Extraenteric amebiasis warrants treatment with other antimicrobial drugs.21

Genital infections/STIs

红霉素可以作为替代药物treating acute pelvic inflammatory disease caused by N. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin.21Syphilis, caused by Treponema pallidum, can be treated with erythromycin. It serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. Erythromycin can also be used in the primary stage of primary syphilis.21Another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. It is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by Chlamydia trachomatis.21呃ythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. Finally, erythromycin is indicated to treat nongonococcal urethritis due to Ureaplasma urealyticum.21

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Macrolides, such as erythromycin, stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections.8呃ythromycin does not exert effects on nucleic acid synthesis.21This drug has been shown to be active against most strains of the following microorganisms, effectively treating both in vitro and clinical infections. Despite this, it is important to perform bacterial susceptibility testing before administering this antibiotic, as resistance is a common issue that may affect treatment.21

A note on antimicrobial resistance, pseudomembranous colitis, and hepatotoxicity

Many strains of Haemophilus influenzae are resistant to erythromycin alone but are found to be susceptible to erythromycin and sulfonamides used in combination. It is important to note that Staphylococci that are resistant to erythromycin may emerge during erythromycin and/or sulfonamide therapy.21与莫Pseudomembranous结肠炎报道st antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, the physician should consider this diagnosis in patients with diarrhea after the administration of antibacterial agents.21呃ythromycin can cause hepatic dysfunction, cholestatic jaundice, and abnormal liver transaminases, particularly when erythromycin estolate is administered.22

Mechanism of action

为了复制,需要一个特定的细菌process of protein synthesis, enabled by ribosomal proteins.9呃ythromycin acts by inhibition of protein synthesis by binding to the 23S ribosomal RNA molecule in the 50S subunit of ribosomes in susceptible bacterial organisms. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit.21,10This results in the control of various bacterial infections.13,21The strong affinity of macrolides, including erythromycin, for bacterial ribosomes, supports their broad‐spectrum antibacterial activities.13

Target Actions Organism
A23S ribosomal RNA
inhibitor
 Enteric bacteria and other eubacteria
NMotilin receptor
agonist
 Humans
NPotassium voltage-gated channel subfamily H member 2
inhibitor
 Humans
Absorption

Orally administered erythromycin is readily absorbed. Food intake does not appear to exert effects on serum concentrations of erythromycin.21Some interindividual variation exists in terms of erythromycin absorption, which may impact absorption to varying degrees.21The Cmax of erythromycin is 1.8 mcg/L15and the Tmax is 1.2 hours.19The serum AUC of erythromycin after the administration of a 500mg oral dose was 7.3±3.9 mg.h/l in one pharmacokinetic study.19呃ythromycin is well known for a bioavailability that is variable (18-45%)6,14after oral administration and its susceptibility to broken down under acidic conditions.5

Volume of distribution

在大多数体液和accu发现红霉素mulates in leucocytes and inflammatory liquid.21,5,19Spinal fluid concentrations of erythromycin are low, however, the diffusion of erythromycin through the blood-brain barrier increases in meningitis, likely due to the presence of inflamed tissues which are easily penetrated.22呃ythromycin crosses the placenta.21

Protein binding

呃ythromycin demonstrates 93% serum protein binding in the erythromycin propionate form.7Another resource indicates that erythromycin protein binding ranges from 80 to 90%.18

Metabolism

Hepatic first-pass metabolism contributes significantly to erythromycin metabolism after an oral dose.11呃ythromycin is partially metabolized by CYP3A4 enzyme to N-desmethylerythromycin.21,8呃ythromycin is also hydrolyzed toanhydroforms (anhydroerythromycin [AHE] and other metabolites), and this process is promoted by acidic conditions.5AHE is inactive against microbes but inhibits hepatic drug oxidation and is therefore considered to be an important contributor to erythromycin drug-drug interactions.5

Hover over products below to view reaction partners

Route of elimination

In patients with normal liver function, erythromycin concentrates in the liver and is then excreted in the bile.22Under 5% of the orally administered dose of erythromycin is found excreted in the urine.22,19A high percentage of absorbed erythromycin is not accounted for, but is likely metabolized.22

Half-life

The elimination half-life of oral erythromycin was 3.5 hours according to one study6and ranged between 2.4-3.1 hours in another study.15Repetitive dosing of erythromycin leads to increased elimination half-life.16

Clearance

The clearance of erythromycin in healthy subjects was 0.53 ± 0.13 l/h/kg after a 125mg intravenous dose.11In a clinical study of healthy patients and patients with liver cirrhosis, clearance of erythromycin was significantly reduced in those with severe liver cirrhosis.17The clearance in cirrhotic patients was 42.2 ± 10.1 l h–1 versus 113.2 ± 44.2 l h-1 in healthy patients.17

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

LD50

The oral LD50 of erythromycin in rats is 9272 mg/kg.23

Overdose information

Symptoms of overdose may include diarrhea, nausea, stomach cramps, and vomiting. Erythromycin should immediately be discontinued in cases of overdose. Rapid elimination of unabsorbed drug should be attempted. Supportive measures should be initiated. Erythromycin is not adequately removed by peritoneal dialysis or hemodialysis.21

Pathways
Pathway Category
呃ythromycin Action Pathway Drug action
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details
Glucose-6-phosphate 1-dehydrogenase Villeurbanne Not Available 1000_1002delACC ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Torun Not Available 1006A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Sunderland Not Available 105_107delCAT ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Iwatsuki Not Available 1081G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Serres Not Available 1082C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Tondela Not Available 1084_1101delCTGAACGAGCGCAAGGCC ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Loma Linda Not Available 1089C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Aachen Not Available 1089C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Tenri Not Available 1096A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Montpellier Not Available 1132G>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Calvo Mackenna Not Available 1138A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Riley Not Available 1139T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Olomouc Not Available 1141T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Tomah Not Available 1153T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Lynwood Not Available 1154G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Madrid Not Available 1155C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Iowa, Walter Reed, Springfield Not Available 1156A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Beverly Hills, Genova, Iwate, Niigata, Yamaguchi Not Available 1160G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Hartford Not Available 1162A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Praha Not Available 1166A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Krakow Not Available 1175T>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Wisconsin Not Available 1177C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Nashville, Anaheim, Portici Not Available 1178G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Alhambra Not Available 1180G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Bari Not Available 1187C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Puerto Limon Not Available 1192G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Covao do Lobo Not Available 1205C>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Clinic Not Available 1215G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Utrecht Not Available 1225C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Suwalki Not Available 1226C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Riverside Not Available 1228G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Japan, Shinagawa Not Available 1229G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kawasaki Not Available 1229G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Munich Not Available 1231A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Georgia Not Available 1284C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Sumare Not Available 1292T->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Telti/Kobe Not Available 1318C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Santiago de Cuba, Morioka Not Available 1339G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Harima Not Available 1358T->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Figuera da Foz Not Available 1366G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Amiens Not Available 1367A>T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Bangkok Noi Not Available 1376G->T, 1502T->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Fukaya Not Available 1462G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Campinas Not Available 1463G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Buenos Aires Not Available 1465C>T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Arakawa Not Available 1466C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Brighton Not Available 1488_1490delGAA ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kozukata Not Available 159G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Amsterdam Not Available 180_182delTCT ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase No name Not Available 202G->A, 376A->G, 1264C>G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Swansea Not Available 224T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Urayasu Not Available 281_283delAGA ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Vancouver Not Available 317C->G544C->T592C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Mt Sinai Not Available 376A->G, 1159C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Plymouth Not Available 488G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Volendam Not Available 514C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Shinshu Not Available 527A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Chikugo Not Available 535A->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Tsukui Not Available 561_563delCTC ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Pedoplis-Ckaro Not Available 573C>G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Santiago Not Available 593G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Minnesota, Marion, Gastonia, LeJeune Not Available 637G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Cincinnati Not Available 637G->T, 1037A->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Harilaou Not Available 648T->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase North Dallas Not Available 683_685delACA ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Asahikawa Not Available 695G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Durham Not Available 713A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Stonybrook Not Available 724_729delGGCACT ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Wayne Not Available 769C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Aveiro Not Available 806G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Cleveland Corum Not Available 820G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Lille Not Available 821A>T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Bangkok Not Available 825G>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Sugao Not Available 826C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase La Jolla Not Available 832T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Wexham Not Available 833C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Piotrkow Not Available 851T>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase West Virginia Not Available 910G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Omiya Not Available 921G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Nara Not Available 953_976delCCACCAAAGGGTACCTGGAC GACC ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Manhattan Not Available 962G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Rehevot Not Available 964T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Honiara Not Available 99A->G/1360C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Tokyo, Fukushima Not Available 1246G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Chatham Not Available 1003G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Fushan Not Available 1004C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Partenope Not Available 1052G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Ierapetra Not Available 1057C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Anadia Not Available 1193A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Abeno Not Available 1220A->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Surabaya Not Available 1291G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Pawnee Not Available 1316G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase S. Antioco Not Available 1342A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Cassano Not Available 1347G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Hermoupolis Not Available 1347G->C/1360C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Union,Maewo, Chinese-2, Kalo Not Available 1360C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Andalus Not Available 1361G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Cosenza Not Available 1376G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Canton, Taiwan- Hakka, Gifu-like, Agrigento-like Not Available 1376G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Flores Not Available 1387C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kaiping, Anant, Dhon, Sapporo-like, Wosera Not Available 1388G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kamogawa Not Available 169C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Costanzo Not Available 179T>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Amazonia Not Available 185C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Songklanagarind Not Available 196T->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Hechi Not Available 202G->A/871G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Namouru Not Available 208T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Bao Loc Not Available 352T>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Crispim Not Available 375G->T, 379G->T383T->C384C>T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Acrokorinthos Not Available 376A->G/463C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Santa Maria Not Available 376A->G/542A->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Ananindeua Not Available 376A->G/871G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Vanua Lava Not Available 383T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Valladolid Not Available 406C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Belem Not Available 409C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Liuzhou Not Available 442G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Shenzen Not Available 473G>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Taipei “Chinese- 3” Not Available 493A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Toledo Not Available 496C>T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Naone Not Available 497G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Nankang Not Available 517T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Miaoli Not Available 519C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Mediterranean, Dallas, Panama‚ Sassari, Cagliari, Birmingham Not Available 563C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Coimbra Shunde Not Available 592C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Nilgiri Not Available 593G>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Radlowo Not Available 679C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Roubaix Not Available 811G>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Haikou Not Available 835A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Chinese-1 Not Available 835A->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Mizushima Not Available 848A>G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Osaka Not Available 853C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Viangchan, Jammu Not Available 871G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Seoul Not Available 916G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Ludhiana Not Available 929G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Farroupilha Not Available 977C->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Chinese-5 Not Available 1024C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Rignano Not Available 130G>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Orissa Not Available 131C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase G6PDNice Not Available 1380G>C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kamiube, Keelung Not Available 1387C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Neapolis Not Available 1400C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Aures Not Available 143T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Split Not Available 1442C->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kambos Not Available 148C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Palestrina Not Available 170G>A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Metaponto Not Available 172G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Musashino Not Available 185C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Asahi Not Available 202G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase A- (202), Ferrara I Not Available 202G->A/376A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Murcia Oristano Not Available 209A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Ube Konan Not Available 241C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Lagosanto Not Available 242G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Guangzhou Not Available 274C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Hammersmith Not Available 323T->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Sinnai Not Available 34G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase A- (680) Not Available 376A->G/680G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase A- (968), Betica,Selma, Guantanamo Not Available 376A->G/968T->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Salerno Pyrgos Not Available 383T>G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Quing Yan Not Available 392G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Lages Not Available 40G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Ilesha Not Available 466G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Mahidol Not Available 487G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Malaga Not Available 542A->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Sibari Not Available 634A->G ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Mexico City Not Available 680G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Nanning Not Available 703C->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Seattle, Lodi, Modena, Ferrara II, Athens-like Not Available 844G->C ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Bajo Maumere Not Available 844G->T ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Montalbano Not Available 854G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Kalyan-Kerala, Jamnaga, Rohini Not Available 949G->A ADRInferred Increased risk of dose-related hemolysis. Details
Glucose-6-phosphate 1-dehydrogenase Gaohe Not Available 95A->G ADRInferred Increased risk of dose-related hemolysis. Details

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be decreased when combined with Erythromycin.
Abametapir The serum concentration of Erythromycin can be increased when it is combined with Abametapir.
Abatacept The metabolism of Erythromycin can be increased when combined with Abatacept.
Abciximab The risk or severity of bleeding can be increased when Erythromycin is combined with Abciximab.
Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.
Abiraterone The metabolism of Abiraterone can be decreased when combined with Erythromycin.
Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.
Acenocoumarol The risk or severity of bleeding can be increased when Erythromycin is combined with Acenocoumarol.
Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Erythromycin.
Acetylcysteine The therapeutic efficacy of Acetylcysteine can be decreased when used in combination with Erythromycin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid grapefruit products.
  • Take on an empty stomach. Allow approximately 30 minutes to 2 hours before meals, as this increases erythromycin absorption.
  • Take with a full glass of water.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
Ingredient UNII 中科院 InChI Key
呃ythromycin estolate XRJ2P631HP 3521-62-8 AWMFUEJKWXESNL-JZBHMOKNSA-N
呃ythromycin ethylsuccinate 1014KSJ86F 1264-62-6 NSYZCCDSJNWWJL-YXOIYICCSA-N
呃ythromycin gluceptate 2AY21R0U64 23067-13-2 ZXBDZLHAHGPXIG-VTXLJDRKSA-N
呃ythromycin lactobionate 33H58I7GLQ 3847-29-8 NNRXCKZMQLFUPL-WBMZRJHASA-N
呃ythromycin phosphate I8T8KU14X7 4501-00-2 VUEMAFLGEMYXIH-YZPBMOCRSA-N
呃ythromycin stearate LXW024X05M 643-22-1 YAVZHCFFUATPRK-YZPBMOCRSA-N
呃ythromycin sulfate KVW9N83AME 7184-72-7 XTSSJGRRFMNXGO-YZPBMOCRSA-N
呃ythromycin thiocyanate Y7A95YRI88 7704-67-8 WVRRTEYLDPNZHR-YZPBMOCRSA-N
Product Images
International/Other Brands
Ilosone (Cipa)
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Akne-mycin Ointment 20 mg/1g Topical Coria Laboratories 1985-01-10 2015-06-30 US flag
E.E.s Granule, for suspension 200 mg/5mL Oral Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2011-04-18 Not applicable US flag
E.E.s Granule, for suspension 200 mg/5mL Oral A S Medication Solutions 2011-04-18 Not applicable US flag
E.E.s Granule, for suspension 200 mg/5mL Oral Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2011-04-18 Not applicable US flag
E.E.S. Suspension 400 mg/5mL Oral UNSPECIFIED 2006-06-05 2006-06-05 US flag
E.E.S. Suspension 200 mg/5mL Oral UNSPECIFIED 2006-06-05 2006-06-05 US flag
E.E.S. Tablet, film coated 400 mg/1 Oral UNSPECIFIED 2006-06-05 2006-06-05 US flag
E.E.S. Granule, for suspension 200 mg/5mL Oral Physicians Total Care, Inc. 1995-02-01 2010-12-31 US flag
E.E.S. Granule, for suspension 200 mg/5mL Oral Abbvie 2010-12-10 2013-09-01 US flag
Ees 600 Tablets 600mg Tablet 600 mg Oral Amdipharm Limited 1983-12-31 2017-06-13 Canada flag
Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Alti-erythromycin Tab 250mg USP Tablet, delayed release 250 mg / tab Oral Altimed Pharma Inc. 1985-12-31 1999-09-17 Canada flag
一些400 Tablet 400 mg/1 Oral Physicians Total Care, Inc. 2011-05-03 2012-06-30 US flag
一些400 Tablet 400 mg/1 Oral Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2011-05-03 Not applicable US flag
E.E.S. Tablet, film coated 400 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 2010-12-16 2016-12-15 US flag
E.E.S. Tablet, film coated 400 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 2010-12-16 2016-12-15 US flag
E.E.S. Suspension 400 mg/5mL Oral Physicians Total Care, Inc. 2000-09-27 2010-12-31 US flag
呃y Swab 20 mg/1mL Topical Padagis Israel Pharmaceuticals Ltd 2008-07-07 Not applicable US flag
呃y Swab 20 mg/1mL Topical bryant ranch prepack 2008-07-07 Not applicable US flag
呃y-tab Tablet, delayed release 250 mg/1 Oral Arbor Pharmaceuticals, Inc. 2011-04-18 Not applicable US flag
呃y-Tab Tablet, delayed release 500 mg/1 Oral Abbott 1982-03-29 2012-06-01 US flag
Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
สตาร์โทรซิน Tablet, film coated 250 mg Oral บริษัท ห้างขายยาตราเจ็ดดาว จำกัด 2000-12-27 2020-09-29 Thailand flag
สตาร์โทรซิน Tablet, film coated 250 mg Oral บริษัท ห้างขายยาตราเจ็ดดาว จำกัด 2008-01-25 2020-09-29 Thailand flag
อีริซิน ขี้ผึ้ง Ointment 2 %w/w Topical บริษัท อังกฤษตรางู (แอล.พี.) จำกัด 2017-02-07 2020-09-29 Thailand flag
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
ACNEMIX % 5 + % 3 JEL, 46.6 GR 呃ythromycin(30 mg/g)+Benzoyl peroxide(50 mg/g) Gel Topical BİLİM İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey flag
AKNEMYCIN PLUS SOLUTION 呃ythromycin(4 g/100g)+Tretinoin(0.025 g/100g) Solution Topical ZUELLIG PHARMA PTE. LTD. 2000-02-04 Not applicable
Aktipak 呃ythromycin(30 mg/1g)+Benzoyl peroxide(50 mg/1g) Gel Topical Cutanea Life Sciences, Inc. 2017-04-10 2019-09-30 US flag
BENZADERM %3+%5 TOPİKAL JEL, 46,6 GRAM 呃ythromycin(3 %)+Benzoyl peroxide(5 %) Gel Topical SOLEBİO İLAÇ SANAYİ İTHALAT İHRACAT A.Ş. 2020-08-14 Not applicable Turkey flag
Benzamycin 呃ythromycin(30 mg/1g)+Benzoyl peroxide(50 mg/1g) Kit Topical Dermik Laboratories 1985-01-01 2016-01-31 US flag
Benzamycin 呃ythromycin(30 mg/1g)+Benzoyl peroxide(50 mg/1g) Kit Topical Bausch Health US, LLC 1984-10-26 Not applicable US flag
Benzamycin 呃ythromycin(3 % w/w)+Benzoyl peroxide(5 % w/w) Gel Topical Bausch Health, Canada Inc. 1996-11-05 Not applicable Canada flag
Benzamycin Pak 呃ythromycin(30 mg/1g)+Benzoyl peroxide(50 mg/1g) Gel Topical Dermik Laboratories 2002-01-01 2014-05-31 US flag
Benzamycin Pak 呃ythromycin(30 mg/1g)+Benzoyl peroxide(50 mg/1g) Gel Topical Valeant Pharmaceuticals North America 2000-11-27 2015-02-18 US flag
BENZAMYCIN TOPIKAL JEL, 46.6 G 呃ythromycin(3 %)+Benzoyl peroxide(5 %) Gel Topical FARMA-TEK İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 2020-04-16 Turkey flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Maxitril 呃ythromycin(0.31 g/0.31g)+Bacitracin zinc(500 [USP'U]/1g) Kit Topical Fusion Pharmaceuticals LLC 2010-02-08 2010-09-01 US flag
Mytrophene 呃ythromycin(0.31 g/0.31g)+Bacitracin zinc(500 [USP'U]/1g) Kit Topical Fusion Pharmaceuticals LLC 2010-05-15 2012-08-31 US flag
Spotex 呃ythromycin(1200 mg/30g) Gel Topical Pella Pharmaceuticals Co. ltd 2013-09-10 Not applicable US flag

Categories

ATC Codes
J01FA01 — Erythromycin D10AF02 — Erythromycin S01AA17 — Erythromycin D10AF52 — Erythromycin, combinations
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues/O-glycosyl compounds/Monosaccharides/Oxanes/叔醇/1,2-aminoalcohols/Trialkylamines/Lactones/Cyclic ketones/Carboxylic acid esters
show 10 more
Substituents
1,2-aminoalcohol/Acetal/Alcohol/Aliphatic heteromonocyclic compound/Amine/Amino acid or derivatives/Aminoglycoside core/羰基/Carboxylic acid derivative/Carboxylic acid ester
show 23 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
erythromycin (CHEBI:42355)/Macrolides and lactone polyketides, Macrolides (C01912)/Macrolides and lactone polyketides (LMPK04000006)
Affected organisms
  • Enteric bacteria and other eubacteria
  • Streptococcus pyogenes
  • Haemophilus influenzae
  • Staphylococcus aureus

Chemical Identifiers

UNII
63937KV33D
中科院number
114-07-8
InChI Key
ULGZDMOVFRHVEP-RWJQBGPGSA-N
InChI
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

References

Synthesis Reference

Takehiro Amano, Masami Goi, Kazuto Sekiuchi, Tomomichi Yoshida, Masahiro Hasegawa, "Process for preparing erythromycin A oxime or a salt thereof." U.S. Patent US5274085, issued October, 1966.

 US5274085
一般引用
  1. Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. [Article]
  2. Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. [Article]
  3. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. [Article]
  4. Houin G, Tillement JP, Lhoste F, Rapin M, Soussy CJ, Duval J: Erythromycin pharmacokinetics in man. J Int Med Res. 1980;8 Suppl 2:9-14. [Article]
  5. Krasniqi S, Matzneller P, Kinzig M, Sorgel F, Huttner S, Lackner E, Muller M, Zeitlinger M: Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy. Antimicrob Agents Chemother. 2012 Feb;56(2):1059-64. doi: 10.1128/AAC.05490-11. Epub 2011 Nov 14. [Article]
  6. Amsden GW: Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996 Jan-Feb;18(1):56-72; discussion 55. [Article]
  7. Gordon RC, Regamey C, Kirby WM: Serum protein binding of erythromycin, lincomycin, and clindamycin. J Pharm Sci. 1973 Jul;62(7):1074-7. [Article]
  8. Fohner AE, Sparreboom A, Altman RB, Klein TE: PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017 Apr;27(4):164-167. doi: 10.1097/FPC.0000000000000270. [Article]
  9. Champney WS, Burdine R: Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Sep;39(9):2141-4. [Article]
  10. Champney WS, Miller M: Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin. Curr Microbiol. 2002 Jun;44(6):418-24. [Article]
  11. Sun H, Frassetto LA, Huang Y, Benet LZ: Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010 Apr;87(4):465-72. doi: 10.1038/clpt.2009.247. Epub 2010 Jan 20. [Article]
  12. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A: Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701. doi: 10.1038/clpt.2011.25. Epub 2011 Mar 30. [Article]
  13. Dinos GP: The macrolide antibiotic renaissance. Br J Pharmacol. 2017 Sep;174(18):2967-2983. doi: 10.1111/bph.13936. Epub 2017 Aug 10. [Article]
  14. Mather LE, Austin KL, Philpot CR, McDonald PJ: Absorption and bioavailability of oral erythromycin. Br J Clin Pharmacol. 1981 Aug;12(2):131-40. doi: 10.1111/j.1365-2125.1981.tb01191.x. [Article]
  15. Wang LQ, Hu ZY, Yu Q, Guo X, Xiong J, Huang ZZ, Cheng ZN: [Pharmacokinetics of erythromycin stinoprate capsule]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Apr;30(2):197-201. [Article]
  16. Colburn WA, Di Santo AR, Gibaldi M: Pharmacokinetics of erythromycin on repetitive dosing. J Clin Pharmacol. 1977 Oct;17(10 Pt 1):592-600. [Article]
  17. 横档J, Mallat Rosenbaum J, Deforges L HouinG, Dhumeaux D, Tillement JP: Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x. [Article]
  18. Periti P, Mazzei T, Mini E, Novelli A: Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989 Apr;16(4):193-214. doi: 10.2165/00003088-198916040-00001. [Article]
  19. Kavi J, Webberley JM, Andrews JM, Wise R: A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J Antimicrob Chemother. 1988 Jul;22 Suppl B:105-10. doi: 10.1093/jac/22.supplement_b.105. [Article]
  20. NIH StatPearls: Erythromycin [Link]
  21. FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension [Link]
  22. MedSafe NZ: ERA (erythromycin stearate) oral filmtabs [Link]
  23. Pfizer: Erythromycin MSDS [Link]
  24. 呃ythromycin estolate monograph [File]
Human Metabolome Database
HMDB0014344
KEGG Drug
D00140
KEGG Compound
C01912
PubChem Compound
12560
PubChem Substance
46508487
ChemSpider
12041
BindingDB
50344942
RxNav
4053
ChEBI
42355
ChEMBL
CHEMBL532
ZINC
ZINC000085534336
Therapeutic Targets Database
DAP000111
PharmGKB
PA449493
PDBe Ligand
ERY
RxList
RxList Drug Page
Drugs.com
Drugs.comDrug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
呃ythromycin
PDB Entries
1jzy/1yi2/2iyf/2j0d/3aoc/3frq/3j5l/3j7z/4m83/4v7u…
show 23 more
MSDS
Download (82.9 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Completed Basic Science Healthy Subjects (HS) 1
4 Completed Prevention Antibiotic Allergy/Antibiotic Side Effect/Eyelid Diseases/Eyelid; Wound/Postoperative Wound Infection/Skin Cancer Face/Surgical Incisions/Surgical Site Infections/Surgical Wound, Recent 1
4 Completed Treatment Acute Obliterating Bronchiolitis/Bronchiolitis Obliterans Syndrome (BOS) 1
4 Completed Treatment Asthma 1
4 Completed Treatment Bacterial blepharitis 1
4 Completed Treatment Healthy Subjects (HS) 1
4 Completed Treatment Pancreatitis 1
4 Recruiting Treatment Acne Vulgaris 1
4 Unknown Status Basic Science Healthy Subjects (HS)/Obesity 1
4 Unknown Status Treatment Familial Adenomatous Polyposis 2

Pharmacoeconomics

Manufacturers
  • Hospira inc
  • Parke davis div warner lambert co
  • Warner chilcott inc
  • Abbott laboratories pharmaceutical products div
  • Barr laboratories inc
  • Stiefel laboratories inc
  • Altana inc
  • Merz pharmaceuticals llc
  • Perrigo co
  • Syosset laboratories inc
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Dista products co div eli lilly and co
  • Dow pharmaceutical sciences inc
  • Paddock laboratories inc
  • Taro pharmaceuticals north america inc
  • Bioglan pharma inc
  • Alpharma us pharmaceuticals division
  • Eli lilly and co
  • Perrigo new york inc
  • Wockhardt eu operations (swiss) ag
  • Hi tech pharmacal co inc
  • 韦斯特伍德施贵宝制药有限公司
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Orthoneutrogena
  • Versapharm inc
  • Ah robins co
  • Solvay pharmaceuticals
  • Watson laboratories inc
  • Life laboratories inc
  • Lilly research laboratories div eli lilly and co
  • Ross laboratories div abbott laboratories inc
  • Pharmacia and upjohn co
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Wyeth ayerst laboratories
  • Abbott laboratories chemical and agricultural products div
  • Mylan pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
  • Bristol laboratories inc div bristol myers co
  • Warner chilcott div warner lambert co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Bristol myers squibb co
  • Pfizer laboratories div pfizer inc
Packagers
  • Abbott Laboratories Ltd.
  • Advanced Pharmaceutical Services Inc.
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Barr Pharmaceuticals
  • Bausch & Lomb Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Casa De Amigos Pharmacy
  • Central Texas Community Health Centers
  • Community Action Inc. Community Health Services
  • Comprehensive Consultant Services Inc.
  • Contract Pharm
  • Core Pharmaceuticals
  • Coria Laboratories
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • Dermik Labs
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • DRX Pharmaceuticals
  • E. Fougera and Co.
  • Eli Lilly & Co.
  • Eye Care and Cure Corp.
  • Eye Supply Usa Inc.
  • Fera Pharmaceuticals
  • H.J. Harkins Co. Inc.
  • Hospira Inc.
  • Inyx Usa Ltd.
  • Ivax Pharmaceuticals
  • 凯泽医院基础l
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mayne Pharma International Pty Ltd.
  • Medical Ophthalmics
  • Medicis Pharmaceutical Co.
  • Medisca Inc.
  • Medvantx Inc.
  • Merz Pharmaceuticals LLC
  • Mississippi State Dept Health
  • Murfreesboro Pharmaceutical Nursing Supply
  • MWI Veterinary Supply Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Nycomed Inc.
  • Ocusoft
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Corporation of America
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmaderm
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Polfa
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Proter SPA
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Seneca Pharmaceuticals Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Tolmar Inc.
  • Tya Pharmaceuticals
  • Valeant Ltd.
  • Veratex Corp.
  • Wa Butler Co.
  • Wilson Ophthalmic Corp.
  • Wockhardt Ltd.
  • X-Gen Pharmaceuticals
Dosage Forms
Form Route Strength
Gel Topical 4 %
Ointment Topical 20 mg/1g
Solution Topical 0.2 g/10g
Solution Oral 20 mg
Solution Topical 4 g/100g
Ointment 20 mg
Tablet, delayed release Oral 250 mg / tab
Suspension Oral 200 mg
Lotion Topical 2 g
Tablet
Granule, for suspension Oral 200 mg/5mL
Tablet, film coated Oral 400 mg/1
Powder, for suspension Oral 40 mg / mL
Tablet Oral 200 mg / tab
Powder, for suspension Oral 400 mg / 5 mL
Gel Topical 4 %w/w
Capsule, liquid filled Oral 500 mg
Granule, for suspension Oral 0.1 %
Granule, for suspension Oral 10 %
Granule, for suspension Oral 1000 MG
Granule, for suspension Oral 500 MG
Injection, solution Intramuscular 0.5 g
Injection, solution Intramuscular 100 MG/2ML
Injection, solution Intravenous 1 g
Solution / drops Oral 200 mg/5ml
Solution / drops Oral 30 ML
Tablet Oral 100 MG
Tablet Oral 250 MG
Tablet Oral 500 MG
Tablet, chewable Oral 200 MG
Tablet, film coated Oral 600 MG
Capsule Oral 0.125 G
Tablet, coated Oral
Tablet, coated Oral 0.250 G
Granule, for suspension Oral
Granule Oral 4 g
Powder, for suspension Oral 5 g
Suspension Oral 5 g
Powder, for suspension Oral 10 g
Tablet, coated Oral 600 mg
Suspension Oral
Tablet, film coated Oral 500 mg
Cream Topical
Gel Topical
Lotion Topical
Injection, powder, for solution Parenteral 1 G/20ML
Injection, powder, for solution Parenteral 500毫克/ 10毫升
Tablet Oral 600 mg
Tablet, coated Oral 500 mg
Suppository
Capsule Oral 250 mg
Injection Intravenous
Swab Topical 20 mg/1mL
Tablet, delayed release Oral 250 mg/1
Tablet, delayed release Oral 333 mg/1
Tablet, delayed release Oral 500 mg/1
Gel Cutaneous
Gel Topical 4 g
Capsule, coated pellets Oral 250 mg/1
Capsule, delayed release pellets Oral 250 mg/1
Capsule, delayed release Oral 250 mg
Capsule, delayed release Oral 333 mg
Cream
Gel Topical 2 %
Solution Topical
Solution Topical
Powder, for suspension Oral 200 mg/5ml
Suspension Oral 200 mg/5mL
Suspension Oral 400 mg/5mL
Wafer Oral 200 mg/1
Granule, for suspension Oral 200 mg
Lotion Topical 2 % w/v
Tablet, coated Oral 250 mg
Granule Oral 1000 MG
Injection, powder, for solution Parenteral
Tablet, film coated Oral
Tablet Oral 250 mg / tab
Tablet Oral 500 mg / tab
Powder, for solution Intravenous 1 g / vial
Powder, for solution Intravenous 500 mg / vial
Injection, powder, for solution Intravenous 1 g/1
Injection, powder, lyophilized, for solution Intravenous 1 g/20mL
Injection, powder, lyophilized, for solution Intravenous 500 mg/100mL
Injection, powder, lyophilized, for solution Intravenous 500 mg/10mL
Liquid Oral 50 mg / mL
Liquid Oral 25 mg / mL
Granule Oral 200 mg/5ml
Granule Oral 400 mg/5ml
Capsule Oral
Capsule, delayed release Oral 250 mg/1
Gel Topical 20 mg/1g
Ointment Ophthalmic 5 mg/1g
Solution Topical 20 mg/1mL
Solution Topical 20 mg/1
Tablet, coated Oral 250 mg/1
Tablet, coated Oral 500 mg/1
Gel; kit Topical
Tablet, film coated Oral 250 mg/1
Tablet, film coated Oral 500 mg/1
Capsule Oral 250 mg / cap
Syrup Oral 200 MG/5ml
For suspension Oral 200 mg/5mL
For suspension Oral 400 mg/5mL
Granule, for suspension Oral 400 mg/5mL
Tablet Oral 400 mg/1
Granule, for suspension Oral
Ointment Ophthalmic 5 mg / g
Tablet Oral 250 mg / cap
Gel Topical
Ointment Topical 0.5 g
Solution / drops Oral
Suspension Oral 125 mg / 5 mL
Solution Topical 2 g
Solution Topical 4 g
Ointment Ophthalmic 0.5 mg/1g
Ointment Ophthalmic .5 %
Powder, for solution Intravenous 1 g / amp
Solution Oral 10 mg
Solution Topical 0.01 g
Ointment Topical 1.667 %
Kit Topical
Capsule, delayed release Oral 250 mg / cap
Suspension Oral 250 mg / 5 mL
Powder Oral 400 mg / 5 mL
Powder, for solution Oral 100 mg / 5 mL
Powder, for solution Oral 200 mg / 5 mL
Ointment Ophthalmic 0.5 %
Tablet Buccal; Oral 4.4 mg
Tablet Oral 333 mg/1
Tablet Oral 333 mg
Tablet Oral 500 mg/1
Powder, for suspension Oral
Lotion Topical
Lotion Topical 0.025 g
Gel Topical 1200 mg/30g
Solution Topical 15 mg/1mL
Solution Oral 2 g
Lotion; swab Topical
Tablet Oral
Syrup Oral
Powder, for solution Topical
Tablet, film coated Oral 250 mg
Tablet, delayed release Oral 250 mg
Ointment Topical 2 %w/w
Powder Oral 125 mg/5ml
Powder, for suspension Oral 125 mg/5ml
Suspension Oral 125 mg/5ml
Prices
Unit description Cost Unit
Benzamycin 5-3% Gel 46.6 gm Jar 236.63USD jar
BenzamycinPak 60 5-3% Packets (2 Box Contains 60 Packets) 142.45USD packet
呃ythromycin 2% Gel 60 gm Tube 46.8USD tube
呃ycette 60 2% Pad Box 30.99USD box
呃ythromycin 2% Gel 30 gm Tube 26.2USD tube
呃ythromycin 2% Solution 60ml Bottle 26.13USD bottle
呃yderm 2% Solution 60ml Bottle 25.99USD bottle
呃ythromycin 5 mg/gm Ointment Limited Supply Available. 13.99USD tube
Benzamycin gel 4.95USD g
Akne-mycin 2% ointment 3.96USD g
PCE 500 mg Enteric Coated Tabs 3.28USD tab
Pce 500 mg dispertab 3.03USD tablet
PCE 333 mg Enteric Coated Tabs 2.48USD tab
呃ythromycin e.s. powder 2.39USD g
Benzamycinpak gel 2.37USD gel
Pce 333 mg dispertab 2.3USD tablet
Romycin eye ointment 1.98USD g
呃ythromycin eye ointment 1.44USD g
Pms-Erythromycin 0.5 % Ointment 1.3USD g
Emgel 2% topical gel 1.07USD g
呃y-Tab 500 mg Enteric Coated Tabs 0.93USD tab
呃y-tab 500 mg tablet ec 0.77USD tablet
呃y-Tab 333 mg Enteric Coated Tabs 0.72USD tab
呃ythro-rx powder 0.72USD g
呃ythromycin ec 500 mg tablet 0.66USD tablet
呃ythromycin Base 500 mg tablet 0.61USD tablet
呃yc 333 mg Capsule (Enteric-Coated Pellet) 0.6USD capsule
Apo-Erythro-S 500 mg Tablet 0.57USD tablet
E-mycin 333 mg tablet ec 0.54USD tablet
呃yc 250 mg Capsule (Enteric-Coated Pellet) 0.54USD capsule
呃ythromycin powder 0.54USD g
呃ythromycin 2% gel 0.5USD g
呃ythromycin Base 250 mg Enteric Coated Capsule 0.5USD capsule
呃ythromycin Base 250 mg tablet 0.5USD tablet
呃y-tab ec 500 mg tablet 0.46USD tablet
Apo-Erythro E-C 333 mg Capsule (Enteric-Coated Pellet) 0.45USD capsule
呃y-Tab 250 mg Enteric Coated Tabs 0.45USD tab
呃ythromycin st 500 mg tablet 0.44USD tablet
Apo-Erythro E-C 250 mg Capsule (Enteric-Coated Pellet) 0.41USD capsule
呃y-tab 333 mg tablet ec 0.4USD tablet
Apo-Erythro-Es 600 mg Tablet 0.35USD tablet
呃ythromycin 500 mg filmtab 0.3USD tablet
呃ythrocin 500 mg filmtab 0.29USD tablet
呃y-tab 250 mg tablet ec 0.27美元 tablet
E.e.s. 400 filmtab 0.25USD tablet
呃ythromycin 250 mg filmtab 0.25USD tablet
呃ythromycin es 400 mg tablet 0.25USD tablet
Apo-Erythro-S 250 mg Tablet 0.22USD tablet
Apo-Erythro Base 250 mg Tablet 0.19USD tablet
呃ythrocin 250 mg filmtab 0.16USD tablet
Novo-Rythro Ees 80 mg/ml Suspension 0.15USD ml
Novo-Rythro Estolate 50 mg/ml Suspension 0.13USD ml
Novo-Rythro Ees 40 mg/ml Suspension 0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Property Value Source
melting point (°C) 133-135 https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx
boiling point (°C) 719.69 https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx
water solubility Soluble in water at 2mg/ml https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx
logP 2.6 http://www.t3db.ca/toxins/T3D4764
logS -3.2 http://www.t3db.ca/toxins/T3D4764
pKa 8.88 https://www.chemicalbook.com/ChemicalProductProperty_US_CB8300078.aspx
Predicted Properties
Property Value Source
Water Solubility 0.459 mg/mL ALOGPS
logP 2.37 ALOGPS
logP 2.6 Chemaxon
logS -3.2 ALOGPS
pKa (Strongest Acidic) 12.45 Chemaxon
pKa (Strongest Basic) 9 Chemaxon
Physiological Charge 1 Chemaxon
Hydrogen Acceptor Count 13 Chemaxon
Hydrogen Donor Count 5 Chemaxon
Polar Surface Area 193.91 Å2 Chemaxon
Rotatable Bond Count 7 Chemaxon
Refractivity 186.04 m3·mol-1 Chemaxon
Polarizability 78.51 Å3 Chemaxon
Number of Rings 3 Chemaxon
Bioavailability 0 Chemaxon
Rule of Five No Chemaxon
Ghose Filter No Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule Yes Chemaxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption + 0.5114
Blood Brain Barrier - 0.9889
Caco-2 permeable - 0.8957
P-glycoprotein substrate Substrate 0.8098
P-glycoprotein inhibitor I Inhibitor 0.8564
P-glycoprotein inhibitor II Non-inhibitor 0.5963
Renal organic cation transporter Non-inhibitor 0.9222
CYP450 2C9 substrate Non-substrate 0.7898
CYP450 2D6 substrate Non-substrate 0.9225
CYP450 3A4 substrate Substrate 0.6528
CYP450 1A2 substrate Non-inhibitor 0.9045
CYP450 2C9 inhibitor Non-inhibitor 0.907
CYP450 2D6 inhibitor Non-inhibitor 0.923
CYP450 2C19 inhibitor Non-inhibitor 0.9074
CYP450 3A4 inhibitor Non-inhibitor 0.5744
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9391
Ames test Non AMES toxic 0.9133
Carcinogenicity Non-carcinogens 0.9335
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.2296 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9902
hERG inhibition (predictor II) Non-inhibitor 0.8956
ADMET数据预测usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
MS/MS Spectrum - DI-ESI-Ion Trap , Positive LC-MS/MS Not Available
MS/MS Spectrum - DI-ESI-Hybrid FT , Positive LC-MS/MS Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-0a7i-0900070700-45f1a3bf3aac26069507
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-0a4i-0900020000-c282d6a703a3a812c91a
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-0a4i-0900000000-b11e26802dca28ea88f0
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-0a4i-0900000000-5ea1e94063a49c0d6ddb
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-004i-0000090000-f0fcdc5ed4d00170f2a3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-0200000900-439b7d31b57ea93dff40
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-0a59-4900000000-1cb488a53f50cba638cf
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9700000000-239fd7095409362c75bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9000000000-37757a9a6c61ec2bac1b
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9000000000-2d04ae69b21d82ee0763
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9000000000-2d04ae69b21d82ee0763
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-053r-0500000900-20a1c46dfdef404c9d3e
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-0a59-5900000000-c7e9166d7e79e23023a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-053r-9800000000-07e4c66bcd0be93f7c09
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9200000000-553fb27002eceacb9270
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9000000000-9725c29b26f7cbbef576
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-001i-9000000000-2d04ae69b21d82ee0763
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-004i-0000090100-c815622b0bac716ba224
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-001i-0000020900-78ac24c4a3447cf2cb78
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-004i-0000090400-0c8362975e5b8d5441bb
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-004i-0200090000-b4daabb8616be713f34c
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-0a4i-0900020000-595b522fe60bb668626a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-004i-0041090000-e9aadb2dff7c545dfce4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-004i-0020092000-6a2a3f6a74deed47dd72
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-056r-0070390000-4f9cd4f2a3b1e945ccfa
LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-0fw9-0004960000-669f9bf82a144b4b5cdb

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.23S ribosomal RNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
In prokaryotes, the 23S rRNA is part of the large subunit (the 50S) that joins with the 30S small subunit to create the functional 70S ribosome. The ribosome is comprised of 3 RNAs: the 23S, the 16S and the 5S ribosomal RNAs. The 23S and the 5S associate with their respective proteins to make up the large subunit of the ribosome, while the 16S RNA associates with its proteins to make up the small subunit.
References
  1. Moazed D, Noller HF: Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 1987 Aug;69(8):879-84. [Article]
  2. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [Article]
  3. Garza-Ramos G, Xiong L, Zhong P, Mankin A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001 Dec;183(23):6898-907. [Article]
  4. Douthwaite S, Aagaard C: Erythromycin binding is reduced in ribosomes with conformational alterations in the 23 S rRNA peptidyl transferase loop. J Mol Biol. 1993 Aug 5;232(3):725-31. [Article]
  5. Wahab HA, Yam WK, Samian MR, Najimudin N: Refinement of a low-resolution crystal structure to better understand erythromycin interactions on large ribosomal subunit. J Biomol Struct Dyn. 2008 Aug;26(1):131-46. [Article]
Details 2.Motilin receptor
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Agonist
General Function
Growth hormone-releasing hormone receptor activity
Specific Function
Receptor for motilin.
Gene Name
MLNR
Uniprot ID
O43193
Uniprot Name
Motilin receptor
分子量
45343.725 Da
References
  1. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G: Erythromycin is a motilin receptor agonist. Am J Physiol. 1989 Sep;257(3 Pt 1):G470-4. [Article]
  2. Deloose E, Vos R, Janssen P, Van den Bergh O, Van Oudenhove L, Depoortere I, Tack J: The motilin receptor agonist erythromycin stimulates hunger and food intake through a cholinergic pathway. Am J Clin Nutr. 2016 Mar;103(3):730-7. doi: 10.3945/ajcn.115.113456. Epub 2016 Jan 27. [Article]
Details 3.Potassium voltage-gated channel subfamily H member 2
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
Curator comments
The majority of references suggest that this drug is a weak inhibitor of the HERG potassium channel.
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
分子量
126653.52 Da
References
  1. Du LP, Tsai KC, Li MY, You QD, Xia L: The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4771-7. [Article]
  2. Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW: Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003 Dec;254(1-2):1-7. [Article]
  3. Crumb WJ Jr: Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels. Br J Pharmacol. 2014 Apr;171(7):1668-75. doi: 10.1111/bph.12575. [Article]

Enzymes

Details 1.Cytochrome P450 3A5
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
分子量
57108.065 Da
References
  1. McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE: Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos. 2004 Oct;32(10):1083-91. doi: 10.1124/dmd.32.10.. [Article]
  2. Lolodi O, Wang YM, Wright WC, Chen T: Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. Curr Drug Metab. 2017;18(12):1095-1105. doi: 10.2174/1389200218666170531112038. [Article]
  3. Flockhart Table of Drug Interactions [Link]
  4. FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension [Link]
Details 2.Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
分子量
57342.67 Da
References
  1. 奥兰多R, Piccoli P·德·马丁,Padrini R,帕拉tini P: Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93. [Article]
  2. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB: CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol. 1999 Nov;48(5):716-27. [Article]
  3. Klotz U: Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung. 2002;52(3):155-61. doi: 10.1055/s-0031-1299873. [Article]
  4. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. [Article]
  5. Flockhart Table of Drug Interactions [Link]
  6. FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension [Link]
  7. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Details 3.Cytochrome P450 3A7
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
分子量
57525.03 Da
References
  1. Torimoto N, Ishii I, Toyama K, Hata M, Tanaka K, Shimomura H, Nakamura H, Ariyoshi N, Ohmori S, Kitada M: Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92. doi: 10.1124/dmd.106.011304. Epub 2006 Dec 18. [Article]
  2. Flockhart Table of Drug Interactions [Link]
  3. FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension [Link]

Transporters

Details 1.Solute carrier organic anion transporter family member 1B3
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
分子量
77402.175 Da
References
  1. Kalliokoski A, Niemi M: Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. [Article]
  2. 康尼锡J:人类OATP fam的吸收转运蛋白ily: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol. 2011;(201):1-28. doi: 10.1007/978-3-642-14541-4_1. [Article]
  3. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A: Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008 Dec;84(6):704-9. doi: 10.1038/clpt.2008.94. Epub 2008 May 28. [Article]
Details 2.Bile salt export pump
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
分子量
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [Article]
  2. Kock K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL: Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos. 2014 Apr;42(4):665-74. doi: 10.1124/dmd.113.054304. Epub 2013 Oct 23. [Article]
  3. Padda MS, Sanchez M, Akhtar AJ, Boyer JL: Drug-induced cholestasis. Hepatology. 2011 Apr;53(4):1377-87. doi: 10.1002/hep.24229. [Article]
Details 3.P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
分子量
141477.255 Da
References
  1. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [Article]
  2. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W: P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther. 2000 Apr;38(4):161-7. [Article]
  3. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700. [Article]
  4. Vadlapatla RK, Vadlapudi AD, Kwatra D, Pal D, Mitra AK: Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33. doi: 10.1016/j.ijpharm.2011.08.009. Epub 2011 Aug 16. [Article]
Details 4.Solute carrier organic anion transporter family member 1B1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
分子量
76447.99 Da
References
  1. Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 Nov;32(11):1239-46. Epub 2004 Jul 30. [Article]
  2. Kalliokoski A, Niemi M: Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. [Article]
  3. 康尼锡J:人类OATP fam的吸收转运蛋白ily: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol. 2011;(201):1-28. doi: 10.1007/978-3-642-14541-4_1. [Article]
  4. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A: Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008 Dec;84(6):704-9. doi: 10.1038/clpt.2008.94. Epub 2008 May 28. [Article]
  5. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A: OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther. 2012 Nov;92(5):642-50. doi: 10.1038/clpt.2012.106. Epub 2012 Sep 19. [Article]
Details 5.Canalicular multispecific organic anion transporter 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
分子量
174205.64 Da
References
  1. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A: Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701. doi: 10.1038/clpt.2011.25. Epub 2011 Mar 30. [Article]
  2. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F: Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013 Sep;52(9):751-62. doi: 10.1007/s40262-013-0069-2. [Article]
  3. Vadlapatla RK, Vadlapudi AD, Kwatra D, Pal D, Mitra AK: Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33. doi: 10.1016/j.ijpharm.2011.08.009. Epub 2011 Aug 16. [Article]
Details 6.Solute carrier organic anion transporter family member 1A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
分子量
74144.105 Da
References
  1. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A: Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008 Dec;84(6):704-9. doi: 10.1038/clpt.2008.94. Epub 2008 May 28. [Article]
  2. Lan T, Rao A, Haywood J, Davis CB, Han C, Garver E, Dawson PA: Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab Dispos. 2009 Dec;37(12):2375-82. doi: 10.1124/dmd.109.028522. Epub 2009 Sep 9. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 19, 2023 09:30